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Tocilizumab in patients admitted to hospital with COVID-19 




Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with 
COVID-19 with both hypoxia and systemic inflammation.
Methods This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy 
[RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial 
participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic 
inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of 
care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given 
intravenously. A second dose could be given 12–24 h later if the patient’s condition had not improved. The primary 
outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN 
(50189673) and ClinicalTrials.gov (NCT04381936).
Findings Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial 
were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. 
Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care 
died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified 
subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more 
likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those 
not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the 
composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; 
p<0·0001).
Interpretation In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved 
survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and 
were additional to the benefits of systemic corticosteroids.
Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
Copyright © 2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 
license.
Introduction
The majority of SARS-CoV-2 infections are either 
asymptomatic or result in only mild disease.1 However, a 
substantial proportion of infected individuals develop a 
respiratory illness requiring hospital care, which can 
progress to critical illness with hypoxic respiratory failure 
requiring prolonged ventilatory support. Among COVID-19 
patients admitted to UK hospitals in spring, 2020, the case 
fatality rate was over 26%, and was in excess of 37% in 
patients requiring invasive mechanical ventilation.2
Hypoxic respiratory failure in patients with COVID-19 is 
associated with evidence of systemic inflammation, 
including release of pro-inflammatory cytokines, such as 
interleukin (IL)-1, IL-6, and tumour necrosis factor α, and 
elevated concentrations of D-dimer, ferritin, and C-reactive 
protein (CRP).3,4 The host immune response is thought to 
play a key role in driving an acute inflammatory pneumonic 
process with diffuse alveolar damage, myeloid cell 
infiltrates, and microvascular thrombosis.5 The beneficial 
effects of dexamethasone and other corticosteroids in 
COVID-19 patients with hypoxic lung damage suggest that 
other, more specific, immuno modulatory agents might 
provide additional improvements in clinical outcomes.6,7
Tocilizumab is a recombinant humanised anti-IL-6 
receptor monoclonal antibody that inhibits the binding of 
IL-6 to both membrane and soluble IL-6 receptors, 
blocking IL-6 signalling and reducing inflammation. 
Tocilizumab is licensed in the UK as an intravenous 
treatment for patients with rheumatoid arthritis and for 
people with chimeric antigen receptor T-cell-induced 
severe or life-threatening cytokine release syndrome. 
Randomised trials of tocilizumab in COVID-19 have so 
far shown mixed results for 28-day mortality: seven small 
trials reported no benefit and the somewhat larger 
Lancet 2021; 397: 1637–45
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REMAP-CAP trial reported a benefit in patients requiring 
organ support.8–15 Here we report the results of a large 
randomised, controlled trial aimed at evaluating the 
effects of tocilizumab in adult patients hospitalised with 
severe COVID-19 characterised by hypoxia and substantial 
inflammation.
Methods
Study design and participants
The Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) trial is an investigator-initiated, individually 
randomised, controlled, open-label, platform trial to 
evaluate the effects of potential treatments in patients 
hospitalised with COVID-19. Details of the trial design 
and results for other possible treatments have been 
published previously.6,16–18 The trial is being done in acute 
National Health Service hospitals in the UK, supported by 
the National Institute for Health Research Clinical 
Research Network (appendix pp 2–25). The trial is 
coordinated by the Nuffield Department of Population 
Health at University of Oxford (Oxford, UK), the trial 
sponsor. The trial is being done in accordance with 
the principles of the International Conference on 
Harmonisation–Good Clinical Practice guidelines and is 
approved by the UK Medicines and Healthcare products 
Regulatory Agency and the Cambridge East Research 
Ethics Committee. The protocol, statistical analysis plan, 
and additional information are available on the study 
website. This report is limited to adult patients. The 
randomised assessment of tocilizumab in children 
younger than 18 years is ongoing.
Patients admitted to hospital were eligible for the study 
if they had clinically suspected or laboratory confirmed 
SARS-CoV-2 infection and no medical history that might, 
in the opinion of the attending clinician, put the patient 
at substantial risk if they were to participate in the trial. 
Written informed consent was obtained from all patients, 
or their legal representative if they were too unwell or 
unable to provide consent.
Randomisation and masking
Data were collected at study entry using a web-based case 
report form that included demographics and major 
comorbidities (appendix p 32). All eligible and consenting 
patients received usual standard of care and underwent 
an initial (main) randomisation comprising up to three 
parts in a factorial design (appendix pp 29–30): part 1, no 
additional treatment versus either dexamethasone, 
lopinavir–ritonavir, hydroxychloroquine, azithromycin, or 
colchicine; part 2, no additional treatment versus either 
convalescent plasma or REGN-COV2 (a combination of 
two monoclonal antibodies directed against SARS-CoV-2 
spike protein); and part 3, no additional treatment versus 
aspirin. Over time, treatment groups were added to and 
removed from the protocol (appendix pp 26–29), and not 
all treatments were available at every hospital. Similarly, 
not all treatments were suitable for some patients 
(eg, owing to comorbid conditions or concomitant 
medication). In any of these cases, randomisation was 
between fewer groups.
Up to 21 days after the main randomisation and 
regardless of treatment allocation, RECOVERY trial 
participants with clinical evidence of progressive 
COVID-19 (defined as oxygen saturation <92% on room 
air or receiving oxygen therapy, and CRP ≥75 mg/L) could 
be considered for randomisation to tocilizumab versus 
usual care alone. Baseline data collected for this 
randomisation included amount of respiratory support, 
markers of progressive COVID-19 (including most recent 
oxygen saturation, CRP, ferritin, and creatinine result 
Research in context
Evidence before this study
We searched MEDLINE, Embase, and MedRxiv from inception 
up to March 5, 2021, for clinical trials or meta-analyses 
evaluating the effect of interleukin-6 inhibitor treatment on 
patients with COVID-19 using the search terms (“COVID-19” 
OR “COVID” OR “SARS-CoV-2” OR “2019-nCoV” OR 
“coronavirus”) AND (“tocilizumab” OR “sarilumab” OR 
“interleukin-6 inhibitor” or “IL-6 inhibitor”).
We identified eight relevant randomised trials that compared 
tocilizumab with usual care or placebo in hospitalised 
patients with COVID-19. All were assessed as at low risk of 
bias. Of these trials, only the REMAP-CAP trial in critically ill 
patients found a significant reduction in 28-day mortality 
with tocilizumab. A meta-analysis of these eight trials, 
which included a total of 439 deaths among 2379 patients 
showed no significant difference in 28-day mortality (death 
rate ratio 0·89, 95% CI 0·72–1·11).
Added value of this study
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) 
trial is the largest randomised trial of the effect of tocilizumab in 
hospitalised patients with COVID-19. We found that in 
4116 COVID-19 patients with hypoxia and a raised C-reactive 
protein, tocilizumab reduced 28-day mortality, increased the 
probability of discharge within 28 days, and, among patients 
who were not receiving invasive mechanical ventilation at 
randomisation, reduced the probability of progression to the 
composite outcome of invasive mechanical ventilation or death. 
The benefits were in addition to corticosteroids and consistent in 
all subgroups, regardless of the amount of respiratory support.
Implications of all the available evidence
Our finding shows that tocilizumab improves survival and other 
clinical outcomes in a broad group of patients hospitalised with 
COVID-19 and that these benefits are additional to those of 
corticosteroids.
For more on the RECOVERY trial 
see www.recoverytrial.net
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before second randomisation), suitability for the study 
treatment, and treatment availability at the site (appendix 
pp 33–34). For some patients, tocilizumab was unavailable 
at the hospital at the time of enrolment or was considered 
by the managing physician to be either definitely 
indicated or definitely contraindicated. In such cases, 
the patients were not eligible for the tocilizumab 
randomisation. Patients with known hypersensitivity to 
tocilizumab, evidence of active tuberculosis infection or 
clear evidence of active bacterial, fungal, viral, or other 
infection (besides COVID-19) were not eligible for 
randomisation to tocilizumab.
Patients who were eligible for randomisation to 
tocilizumab were assigned to either usual standard of care 
or usual standard of care plus tocilizumab in a 1:1 ratio by 
means of web-based simple (unstratified) randomisation 
with allocation concealed until after randomisation. 
Allocated treatment was prescribed by the managing 
doctor. Roche Products (Welwyn Garden City, UK) 
supported the trial through provision of tocilizumab. 
Participants and local study staff were not masked to the 
allocated treatment. The steering committee, investigators, 
and all others involved in the trial were masked to the 
outcome data during the trial.
Procedures
Patients allocated to tocilizumab were to receive 
tocilizumab as a single intravenous infusion over 
60 min. The dose of tocilizumab was established by 
bodyweight (800 mg if weight >90 kg; 600 mg if 
weight >65 and ≤90 kg; 400 mg if weight >40 and ≤65 kg; 
and 8 mg/kg if weight ≤40 kg). A second dose could be 
given 12–24 h later if, in the opinion of the attending 
clinician, the patient’s condition had not improved.
A single online follow-up form was completed when 
participants were discharged, had died, or at 28 days after 
Tocilizumab group 
(n=2022)
Usual care group 
(n=2094)
Age, years 63·3 (13·7) 63·9 (13·6)
≥18 to <70 1331 (66%) 1355 (65%)
≥70 to <80 478 (24%) 480 (23%)
≥80 213 (11%) 259 (12%)
Sex
Male 1337 (66%) 1437 (69%)
Female* 685 (34%) 657 (31%)
Ethnicity
White 1530 (76%) 1597 (76%)
Black, Asian, or minority 
ethnic
354 (18%) 378 (18%)
Unknown 138 (7%) 119 (6%)
Number of days since symptom 
onset
9 (7–13) 10 (7–14)
Number of days since 
hospitalisation
2 (1–5) 2 (1–5)
Oxygen saturation 94% (92–96) 94% (91–95)
Respiratory support at second randomisation
No ventilator support† 935 (46%) 933 (45%)
Non-invasive ventilation‡ 819 (41%) 867 (41%)
Invasive mechanical 
ventilation§
268 (13%) 294 (14%)
Biochemistry at second randomisation
Latest C-reactive protein, 
mg/L
143 (107–203) 144 (106–205)
Ferritin, ng/mL 947 (497–1599) 944 (507–1533)
Creatinine, µmol/L 77 (62–98) 77 (62–100)
Previous diseases
Diabetes 569 (28%) 600 (29%)
Heart disease 435 (22%) 497 (24%)
Chronic lung disease 473 (23%) 484 (23%)
Tuberculosis 3 (<1%) 5 (<1%)
HIV 7 (<1%) 8 (<1%)
Severe liver disease¶ 14 (1%) 10 (<1%)
Severe kidney impairment|| 118 (6%) 99 (5%)
Any of the above 1100 (54%) 1163 (56%)
(Table 1 continues in next column)
Tocilizumab group 
(n=2022)
Usual care group 
(n=2094)
(Continued from previous column)
SARS-CoV-2 test result
Positive 1922 (95%) 2005 (96%)
Negative 69 (3%) 71 (3%)
Not known 31 (2%) 18 (1%)
First randomisation**
Number of days since first 
randomisation
0 (0–1) 0 (0–1)
Part A allocation
Usual care 839 (41%) 869 (41%)
Lopinavir–ritonavir 51 (3%) 64 (3%)
Dexamethasone 49 (2%) 45 (2%)
Hydroxychloroquine 37 (2%) 38 (2%)
Azithromycin 197 (10%) 177 (8%)
Use of systemic corticosteroids††
Yes 1664 (82%) 1721 (82%)
No 357 (18%) 367 (18%)
Unknown 1 (<1%) 6 (<1%)
Data are mean (SD), n (%), or median (IQR). Information on sex, ethnicity, and 
SARS-CoV-2 test result were recorded on the main randomisation form when 
patients first entered the study. All other information was recorded on the second 
randomisation form (when patients were randomly assigned to tocilizumab vs 
usual care alone). *Includes ten pregnant women. †Includes nine patients not 
receiving any oxygen and 1859 patients receiving low-flow oxygen. ‡Includes 
patients receiving high-flow nasal oxygen, continuous positive airway pressure, or 
other non-invasive ventilation. §Includes patients receiving invasive mechanical 
ventilation or extracorporeal membranous oxygenation. ¶Defined as requiring 
ongoing specialist care. ||Defined as estimated glomerular filtration rate 
<30 mL/min per 1·73 m². **2631 participants were randomly assigned into part B 
and 1615 into part C of the first randomisation. ††Information on use of 
corticosteroids was collected from June 18, 2020, onwards following 
announcement of the results of the dexamethasone comparison from the 
RECOVERY trial. Participants undergoing first randomisation before this date 
(and who were not allocated to dexamethasone) are assumed not to be receiving 
systemic corticosteroids.
Table 1: Baseline characteristics
Articles
1640 www.thelancet.com   Vol 397   May 1, 2021
the initial randomisation, whichever occurred earliest 
(appendix pp 35–41). Information was recorded on 
adherence to allocated study treatment, receipt of other 
COVID-19 treatments, duration of admission, receipt of 
respiratory or renal support, and vital status (including 
cause of death). In addition, routine health-care and 
registry data were obtained for the full follow-up period, 
including information on vital status (with date and 
cause of death), discharge from hospital, receipt of 
respiratory support, or renal replacement therapy.
Outcomes
Outcomes were assessed at 28 days after randomisation to 
tocilizumab versus usual care alone, with further analyses 
specified at 6 months. The primary outcome was all-cause 
mortality. Secondary outcomes were time to discharge 
from hospital, and, among patients not receiving invasive 
mechanical ventilation at randomisation, receipt of 
invasive mechanical ventilation (including extracorporeal 
membrane oxygenation) or death. Prespecified subsidiary 
clinical outcomes were use of non-invasive respiratory 
support (defined as high-flow nasal oxygen, continuous 
positive airway pressure, or non-invasive ventilation), time 
to successful cessation of invasive mechanical ventilation 
(defined as cessation of invasive mechanical ventilation 
within, and survival to, 28 days), and use of renal dialysis 
or haemofiltration. Prespecified safety outcomes included 
cause-specific mortality and major cardiac arrhythmia. 
Information on suspected serious adverse reactions was 
collected in an expedited fashion to comply with regulatory 
requirements.
Statistical analysis
In accordance with the statistical analysis plan 
(version 2.1, appendix pp 93–117), an intention-to-treat 
comparison was done between patients who entered the 
randomised comparison of tocilizumab versus usual 
care. For the primary outcome of 28-day mortality, the 
log-rank observed minus expected statistic and its 
variance were used to test the null hypothesis of equal 
survival curves (ie, the log-rank test) and to calculate the 
one-step estimate of the average mortality rate ratio. We 
Figure 1: Trial profile
REGN-COV2=a combination of two monoclonal antibodies directed against SARS-CoV-2 spike protein. *Number 
of adult patients recruited at a site activated for the tocilizumab comparison. †The first randomisation 
comprised up to three factorial elements such that an eligible patient could be entered into between one and 
three randomised comparisons, depending on the then current protocol, the patient's suitability for particular 
treatments, and the availability of the treatment at the site. Median time between first and second 
randomisation was 0·3 h (IQR 0·1−25·3). ‡1964 (97%) of 2022 patients of those allocated to tocilizumab and 
2049 (98%) of 2094 of those allocated to usual care had a completed follow-up form at time of analysis.
2022 allocated to tocilizumab
1647 received tocilizumab‡  
3 consent withdrawn  4 consent withdrawn  
2094 allocated to usual care alone
77 received tocilizumab‡  
2022 included in 28-day intention-to-treat analysis 2094 included in 28-day intention-to-treat analysis  
21 550 patients recruited* 
4116 randomly assigned between
tocilizumab and usual care alone 
First randomisation†






Part B: 5285 convalescent plasma
2416 REGN−COV2
6301 usual care
Part C: 4450 aspirin
4594 usual care
17 434 did not proceed to second randomisation
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or contraindicated medical history)
Figure 2: Effect of allocation to tocilizumab on 28-day mortality (A) and 
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constructed Kaplan-Meier survival curves to display 
cumulative mortality over the 28-day period. We used 
the same method to analyse time to hospital discharge 
and successful cessation of invasive mechanical 
ventilation, with patients who died in hospital right-
censored on day 29. For the prespecified composite 
secondary outcome of invasive mechanical ventilation or 
death within 28 days (among those not receiving invasive 
mechanical ventilation at randomisation) and the 
subsidiary clinical outcomes of receipt of ventilation and 
receipt of haemodialysis or haemofiltration, the precise 
dates were not available and so the risk ratio was 
estimated instead.
Prespecified analyses of the primary outcome were 
done in subgroups defined by six characteristics at the 
time of randomisation: age, sex, ethnicity, amount of 
respiratory support, days since symptom onset, and use 
of systemic corticosteroids (including dexamethasone). 
Observed effects within subgroup categories were 
compared by means of a χ² test for heterogeneity or 
trend, in accordance with the prespecified analysis plan.
Estimates of rate and risk ratios are shown with 
95% CIs. All p values are two-sided and are shown 
without adjustment for multiple testing. The full 
database is held by the study team which collected the 
data from study sites and did the analyses at the Nuffield 
Department of Population Health, University of Oxford 
(Oxford, UK).
Before commencement of the randomisation to 
tocilizumab versus usual care, the trial steering 
committee determined that if 28-day mortality in the 
usual care group was above 25% then recruitment of 
around 4000 patients to this comparison would provide 
90% power at two-sided p=0·01 to detect a proportional 
reduction in 28-day mortality of one-fifth. Consequently, 
Roche Products provided sufficient treatment for 
2000 patients to receive tocilizumab. The trial steering 
committee, masked to the results, closed recruitment to 
the tocilizumab comparison at the end of Jan 24, 2021, as 
over 4000 patients had been randomly assigned.
For the primary outcome of 28-day mortality, the 
results from RECOVERY were subsequently included in 
a meta-analysis of results from all previous randomised 
trials of tocilizumb versus usual care in patients with 
COVID-19. For each trial, we compared the observed 
number of deaths among patients allocated tocilizumab 
with the expected number if all patients were at equal 
risk (ie, we calculated the observed minus expected 
statistic [o–e], and its variance v). For RECOVERY, these 
were taken as the log-rank observed minus expected 
statistic and its variance but for other trials, where the 
exact timing of each death was not available, these were 
calculated from standard formulae for 2 × 2 contingency 
tables. We then combined trial results using the log of 
the mortality rate ratio calculated as the inverse-variance 
weighted average S/V with variance 1/V (and hence with 
95% CI S/V ±1·96/√V), where S is the sum over all trials 
of (O–E) and V is the sum over all trials of v.19 Analyses 
were done by means of SAS version 9.4 and R version 3.4. 
The trial is registered with ISRCTN (50189673) and 
ClinicalTrials.gov (NCT04381936).
Role of the funding source
Neither the funders of the study nor Roche Products had 
any role in study design, data collection, data analysis, 
data interpretation, or writing of the report. Roche 
Products supported the study through the supply of 
tocilizumab and reviewed the draft publication for factual 
accuracy relating to tocilizumab.
Results
Between April 23, 2020, and Jan 24, 2021, 4116 (19%) of 
21 550 patients enrolled into the RECOVERY trial at one 
of the 131 sites in the UK participating in the tocilizumab 
comparison were eligible for random assignment. 
2022 patients were randomly allocated to tocilizumab and 
2094 were randomly allocated to usual care. The mean 
age of these participants was 63·6 years (SD 13·6). At 
randomisation, 562 (14%) of 4116 patients were receiving 
invasive mechanical ventilation, 1686 (41%) of 4116 were 
receiving non-invasive respiratory support (including 
high-flow nasal oxygen, continuous positive airway 
pressure, and non-invasive ventilation), and 1868 (45%) of 
Treatment allocation RR (95% CI) p value
Tocilizumab group 
(n=2022)
Usual care group 
(n=2094)
Primary outcome
28-day mortality 621 (31%) 729 (35%) 0·85 (0·76–0·94) 0·0028
Secondary outcomes
Median time to being 
discharged, days
19 >28 ·· ··
Discharged from hospital 
within 28 days
1150 (57%) 1044 (50%) 1·22 (1·12–1·33) <0·0001
Receipt of invasive mechanical 
ventilation or death*
619/1754 (35%) 754/1800 (42%) 0·84 (0·77–0·92) <0·0001
Invasive mechanical 
ventilation
265/1754 (15%) 343/1800 (19%) 0·79 (0·69–0·92) 0·0019
Death 490/1754 (28%) 580/1800 (32%) 0·87 (0·78–0·96) 0·0055
Subsidiary clinical outcomes
Receipt of ventilation† 290/935 (31%) 323/933 (35%) 0·90 (0·79–1·02) 0·10
Non-invasive ventilation 281/935 (30%) 309/933 (33%) 0·91 (0·79–1·04) 0·15
Invasive mechanical 
ventilation
67/935 (7%) 86/933 (9%) 0·78 (0·57–1·06) 0·11
Successful cessation of invasive 
mechanical ventilation‡
95/268 (35%) 98/294 (33%) 1·08 (0·81–1·43) 0·60
Use of haemodialysis or 
haemofiltration§
120/1994 (6%) 172/2065 (8%) 0·72 (0·58–0·90) 0·0046
Data are n (%), n/N (%), or median (IQR) unless stated otherwise. RR=rate ratio for the outcomes of 28-day mortality, 
hospital discharge, and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. 
*Analyses include only those on no ventilator support or non-invasive ventilation at second randomisation. †Analyses 
include only those on no ventilator support at second randomisation. ‡Analyses restricted to those on invasive 
mechanical ventilation at second randomisation. §Analyses exclude those on haemodialysis or haemofiltration at 
second randomisation.
Table 2: Effect of allocation to tocilizumab on main study outcomes
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4116 were receiving no respiratory support other than 
simple oxygen therapy (nine of these patients were 
reportedly not receiving oxygen at randomisation; table 1). 
Median CRP was 143 (IQR 107–204) mg/L. 82% of 
patients were reported to be receiving corticosteroids at 
randomisation (and 97% of the patients enrolled since the 
announcement of the dexamethasone result from 
RECOVERY in June, 2020).
The follow-up form was completed for 1964 (97%) of 
2022 randomly assigned patients in the tocilizumab 
group and 2049 (98%) of 2094 patients in the usual care 
group. Among patients with a completed follow-up form, 
1647 (84%) of 1964 allocated to tocilizumab and 77 (4%) of 
2049 of those allocated to usual care received at least 
one dose of tocilizumab (or sarilumab, another IL-6 
antagonist; figure 1; appendix p 44). 565 (29%) of 
1964 patients in the tocilizumab group and 17 (1%) of 
2049 in the usual care group received more than one 
dose of tocilizumab (or sarilumab). Use of other 
treatments for COVID-19 during the 28 days after 
randomisation was similar among patients allocated 
tocilizumab and among those allocated usual care 
(appendix p 44). Follow-up for the primary and secondary 
outcomes was complete for 99% of randomised 
participants.
Allocation to tocilizumab was associated with a 
significant reduction in the primary outcome of 28-day 
mortality compared with usual care alone (621 [31%] of 
2022 patients in the tocilizumab group vs 729 (35%) of 
2094 patients in the usual care group; rate ratio 0·85; 
95% CI, 0·76–0·94; p=0·0028; figure 2A). In an 
exploratory analysis restricted to the 3927 (95%) patients 
with a positive SARS-CoV-2 test result, the result was 
similar (rate ratio 0·86, 95% CI 0·77–0·97; p=0·0098).
Allocation to tocilizumab was associated with a greater 
probability of discharge from hospital within 28 days 
(57% vs 50%; rate ratio 1·22, 1·12–1·33, p<0·0001; figure 2B 
and table 2). Among those not on invasive mechanical 
ventilation at baseline, allocation to tocilizumab was 
associated with a reduction in the risk of progressing to the 
prespecified composite secondary outcome of invasive 
mechanical ventilation or death when compared with usual 
care alone (35% vs 42%, risk ratio 0·84, 0·77–0·92, 
p<0·0001; table 2).
We observed similar results across all prespecified 
subgroups (figure 3, appendix pp 48–49), including the 
Figure 3: Effect of allocation to tocilizumab on 28-day mortality by baseline characteristics
Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines 
through them correspond to the 95% CIs. *Includes nine patients not receiving any oxygen and 1859 patients receiving simple oxygen only. †Includes patients 
receiving high-flow nasal oxygen, continuous positive airway pressure ventilation, and other non-invasive ventilation. ‡Includes patients receiving invasive mechanical 
ventilation and extracorporeal membranous oxygenation. §Information on use of corticosteroids was collected from June 18, 2020, onwards following announcement 
of the results of the dexamethasone comparison from the RECOVERY trial. Participants undergoing first randomisation before this date (and who were not allocated to 
dexamethasone) are assumed not to be receiving systemic corticosteroids. In a model adjusted for all six baseline subgroups (in the categories shown) the overall rate 
ratio was 0·88 (95% CI 0·79−0·98).
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amount of respiratory support at randomisation (figure 3). 
Given the number of hypothesis tests done, the suggestion 
of a larger proportional mortality reduction among those 
receiving a corticosteroid compared with those not 
(interaction p=0·01) might reflect the play of chance. An 
exploratory analysis showed that the effects of tocilizumab 
on 28-day mortality were similar for those randomly 
assigned ≤2 or >2 days since hospitalisation (interaction 
p=0·89). In eight previous trials of tocilizumab versus 
usual care, which included a total of 439 deaths among 
2379 patients, allocation to tocilizumab was associated 
with a non-significant 11% reduction in mortality (rate 
ratio 0·89, 0·72–1·11; figure 4). After inclusion of the 
28-day mortality results from RECOVERY into this meta-
analysis, the mortality rate ratio from the nine trials 
was 0·86 (0·78–0·94), p=0·0017.
In prespecified subsidiary analyses, we found no 
significant effect of tocilizumab on subsequent receipt of 
non-invasive respiratory support or invasive mechanical 
ventilation among those on no respiratory support at 
randomisation (table 2, appendix p 50). Nor was there a 
significant effect on the rate of successful cessation of 
invasive mechanical ventilation among those on invasive 
mechanical ventilation at randomisation. However, 
alloca tion to tocilizumab reduced the use of haemo-
dialysis or haemofiltration (6% vs 8%, risk ratio 0·72, 
0·58–0·90, p=0·0046; table 2) among those not 
receiving haemodialysis or haemofiltration at randomi-
sation. There was no evidence of excess deaths from 
non-COVID infections or other causes (appendix p 45). 
We observed no significant differences in the frequency 
of new cardiac arrhythmias (appendix p 46). There were 
three reports of serious adverse reactions believed to be 
related to tocilizumab: one each of otitis externa, 
Staphylococcus aureus bacteraemia, and lung abscess, all 
of which resolved with standard treatment.
Discussion
The results of this large, randomised trial indicate that 
tocilizumab is an effective treatment for hospitalised 
COVID-19 patients who have hypoxia and evidence 
of inflammation (CRP ≥75 mg/L). Treatment with 
tocilizumab improved survival and the chances of 
discharge from hospital by 28 days, and reduced the 
chances of progressing to require invasive mechanical 
ventilation. These benefits were consistent across all 
patient groups studied, including those receiving 
invasive mechanical ventilation, non-invasive respiratory 
support, or no respiratory support other than simple 
oxygen. The benefits of tocilizumab were clearly seen 
among those also receiving treatment with a systemic 
corticosteroid, which is now usual standard of care for 
COVID-19 patients requiring treatment with oxygen.6,7
Previous trials have provided some evidence that 
tocilizumab might shorten time to discharge or reduce 
progression to invasive mechanical ventilation or 
death.9,13 Since mid-2020, eight randomised, controlled 
trials of tocilizumab for the treatment of COVID-19 have 
reported. These include seven small trials (fewer than 
100 deaths in each) and the somewhat larger 
REMAP-CAP trial, which recruited critically ill patients 
with COVID-19, over 99% of whom required non-invasive 
respiratory support or invasive mechanical ventilation.8–15 
Taken together, these previous trials did not show a 
significant mortality benefit for treatment with 
tocilizumab (death rate ratio 0·89, 95% CI 0·72–1·11; 
figure 4). The RECOVERY trial contains around 
four times as much information as all the previous trials 
Figure 4: Meta-analysis of mortality in randomised, controlled trials of tocilizumab in patients hospitalised with COVID-19
O–E=observed–expected. Var=variance. *Log−rank O−E for RECOVERY, O−E from 2 × 2 contingency tables for the other trials. Rate ratio is calculated by taking ln rate 
ratio to be (O−E)/V with normal variance 1/V, where V=Var (O–E). Subtotals or totals of (O−E) and of V yield inverse-variance weighted averages of the ln rate ratio 
values. †For balance, controls in the 2:1 studies count twice in the control totals and subtotals, but do not count twice when calculating their O−E or V values. 
Heterogeneity between RECOVERY and eight previous trials combined, χ₁²=0·2 (p=0·7).
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combined. When all nine trials are considered together, 
allocation to tocilizumab is associated with a significant 
14% proportional reduction in 28-day mortality. These 
results suggest that in COVID-19 patients who are 
hypoxic and have evidence of systematic inflammation, 
treatment with a combination of a systemic corticosteroid 
plus tocilizumab would be expected to reduce mortality 
by about one-third for patients receiving simple oxygen 
and nearly one-half for those receiving invasive 
mechanical ventilation.6
The RECOVERY results support the use of tocilizumab. 
Our results show that the benefits of tocilizumab extend 
to a broad group of patients receiving oxygen, with or 
without other forms of respiratory support, and that 
those benefits include a reduction in the need for invasive 
mechanical ventilation and renal replacement therapy. 
Since complicating bacterial infections are infrequent 
in the early hospitalisation period of COVID-19, this 
recognised concern in relation to the use of tocilizumab 
would be lessened with earlier use.20 On the basis of the 
ISARIC4C database, approximately 49% of hospitalised 
COVID-19 patients in the UK would meet our inclusion 
criteria and hence would benefit from tocilizumab 
(ISARIC4C Investigators, personal communication). 
Sarilumab, an alternative IL-6 antagonist, is available but 
evidence of its efficacy is inconclusive15,21,22 and the results 
of the largest trial (NCT04315298) are not yet published.
Strengths of this trial included that it was randomised, 
had a large sample size, and included patients requiring 
various amounts of respiratory support (from simple 
oxygen through to invasive mechanical ventilation) and 
has 99% completeness of follow-up for the primary 
outcome. CRP was chosen as the biomarker for inflam-
mation in this study since it is widely used and affordable 
worldwide, it is correlated with serum IL-6 concentrations, 
and early clinical studies of COVID-19 had reported it to 
be associated with severity and prognosis, with a value of 
greater than 50 mg/L associated with severe disease and 
a concentration of around 75 mg/L distinguishing fatal 
from non-fatal cases.23–28 Whether hypoxic patients with a 
CRP of less than 75 mg/L could benefit from tocilizumab 
is unknown. There are some limitations. We did not 
collect detailed information on non-COVID infections. 
Following random assignment, 16% of patients in the 
tocilizumab group reportedly did not receive this 
treatment and the reasons for this were not recorded. 
The size of the effects of tocilizumab reported in this 
paper are therefore an underestimate of the true effects 
of actually using the treatment. Hospital stay is very long 
for many of these patients and some outcomes beyond 
28 days have not yet been captured. The preplanned 
analyses at 6 months will, however, provide additional 
information on the full effects of tocilizumab on clinical 
outcomes. Further work is also needed to consider the 
health economic benefits of tocilizumab and related IL-6 
inhibitors in terms of both patient outcomes and usage 
of health-care resources (duration of hospital stay, and 
frequency of invasive mechanical ventilation and renal 
replacement therapy).
The RECOVERY trial has shown that for patients 
hospitalised with severe COVID-19, treatment with 
tocilizumab reduces mortality, increases the chances of 
successful hospital discharge, and reduces the chances of 
requiring invasive mechanical ventilation. These benefits 
are additional to those previously reported for dexa-
methasone. These findings require an update to clinical 
guidelines, which has already begun, and efforts to increase 
the global availability and affordability of tocilizumab.29,30
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